Barclays
KALV

Barclays’s KalVista Pharmaceuticals KALV Stock Holding History

Barclays’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.8M Sell
537,061
-163,512
-23% -$2.64M ﹤0.01% 1412
2025
Q4 		$11.3M Buy
700,573
+122,669
+21% +$1.62M ﹤0.01% 1600
2025
Q3 		$7.04M Buy
577,904
+408,981
+242% +$5.65M ﹤0.01% 1950
2025
Q2 		$1.91M Buy
168,923
+113,696
+206% +$1.39M ﹤0.01% 2884
2025
Q1 		$637K Sell
55,227
-12,835
-19% -$131K ﹤0.01% 3375
2024
Q4 		$576K Buy
68,062
+840
+1% +$8.7K ﹤0.01% 3736
2024
Q3 		$778K Buy
67,222
+54,257
+418% +$682K ﹤0.01% 3518
2024
Q2 		$153K Sell
12,965
-8,990
-41% -$105K ﹤0.01% 3712
2024
Q1 		$260K Sell
21,955
-20,576
-48% -$274K ﹤0.01% 3975
2023
Q4 		$521K Buy
42,531
+38,316
+909% +$349K ﹤0.01% 3844
2023
Q3 		$40.6K Sell
4,215
-691
-14% -$7.06K ﹤0.01% 3950
2023
Q2 		$44.2K Sell
4,906
-7,507
-60% -$69.2K ﹤0.01% 3895
2023
Q1 		$97.6K Buy
12,413
+5,841
+89% +$43.6K ﹤0.01% 4197
2022
Q4 		$44.4K Buy
6,572
+3,923
+148% +$21K ﹤0.01% 4591
2022
Q3 		$38K Buy
2,649
+679
+34% +$9.49K ﹤0.01% 3861
2022
Q2 		$19K Sell
1,970
-1,668
-46% -$18.4K ﹤0.01% 4424
2022
Q1 		$54K Sell
3,638
-25,348
-87% -$364K ﹤0.01% 4090
2021
Q4 		$383K Buy
28,986
+18,582
+179% +$296K ﹤0.01% 3313
2021
Q3 		$181K Buy
10,404
+5,335
+105% +$108K ﹤0.01% 3669
2021
Q2 		$122K Sell
5,069
-28,214
-85% -$738K ﹤0.01% 3768
2021
Q1 		$854K Buy
33,283
+19,603
+143% +$515K ﹤0.01% 2868
2020
Q4 		$260K Sell
13,680
-978
-7% -$16.8K ﹤0.01% 3616
2020
Q3 		$185K Buy
14,658
+657
+5% +$8.21K ﹤0.01% 3898
2020
Q2 		$169K Buy
14,001
+3,322
+31% +$35.3K ﹤0.01% 4187
2020
Q1 		$82K Sell
10,679
-14,217
-57% -$192K ﹤0.01% 4924
2019
Q4 		$444K Buy
24,896
+6,862
+38% +$89.6K ﹤0.01% 4398
2019
Q3 		$209K Sell
18,034
-4,973
-22% -$80.3K ﹤0.01% 4933
2019
Q2 		$510K Sell
23,007
-9,482
-29% -$222K ﹤0.01% 4306
2019
Q1 		$930K Sell
32,489
-30,289
-48% -$657K ﹤0.01% 3478
2018
Q4 		$1.24M Buy
62,778
+62,707
+88,320% +$1.26M ﹤0.01% 2898
2018
Q3 		$2K Buy
+71
New +$960 ﹤0.01% 6945
2018
Q1 		– Sell
-1,349
Closed -$13K – 7193
2017
Q4 		$13K Buy
+1,349
New +$14K ﹤0.01% 6445
2016
Q3 		– Sell
-32
Closed – – 6703
2016
Q2 		$0 Buy
+32
New +$371 ﹤0.01% 6470
2015
Q4 		– Sell
-5
Closed – – 6272
2015
Q3 		$0 Sell
5
-12
-71% -$1.02K ﹤0.01% 6943
2015
Q2 		$2K Buy
+17
New +$1.69K ﹤0.01% 6805

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays's KALV Position: Q1 2026 in Review

Barclays reduced its KalVista Pharmaceuticals (KALV) stake by 23% in Q1 2026, selling an estimated $2.64M and leaving 537,061 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1412.

Barclays first reported a position in KALV in Q2 2015 and has held it in 35 quarters since. The position peaked at $11.3M in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Barclays held 537,061 shares of KalVista Pharmaceuticals worth $10.8M as of Q1 2026.
  • Barclays sold 163,512 KalVista Pharmaceuticals shares in Q1 2026, an estimated $2.64M.
  • KalVista Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1412 holding.
  • Barclays first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 35 quarters since.
  • Barclays's KalVista Pharmaceuticals position peaked at $11.3M in Q4 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.